Anika Therapeutics Stock (NASDAQ:ANIK)


RevenueOwnershipFinancialsChartTranscripts

Previous Close

$24.68

52W Range

$16.00 - $29.12

50D Avg

$24.95

200D Avg

$25.45

Market Cap

$253.17M

Avg Vol (3M)

$50.08K

Beta

0.83

Div Yield

-

ANIK Company Profile


Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

357

IPO Date

May 03, 1993

Website

ANIK Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Non-Orthopedic$9.86M$7.95M$9.70M
Joint Preservation and Restoration$54.88M$50.40M$48.59M
OA Pain Management-$97.89M$89.50M
Licensing, Milestone and Contract Revenue---
Product--$147.79M

Fiscal year ends in Dec 23 | Currency in USD

ANIK Financial Summary


Dec 23Dec 22Dec 21
Revenue$166.66M$156.24M$147.79M
Operating Income$-25.45M$-19.40M$-18.48M
Net Income$-82.67M$-14.86M$4.13M
EBITDA$-11.21M$-19.40M$-39.58M
Basic EPS$-5.64$-1.02$0.29
Diluted EPS$-5.64$-1.02$0.28

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 11, 24 | 1:49 AM
Q1 24May 08, 24 | 12:00 AM
Q4 23Mar 13, 24 | 7:17 PM

Peer Comparison


TickerCompany
FNAParagon 28, Inc.
OFIXOrthofix Medical Inc.
AVNSAvanos Medical, Inc.
SGHTSight Sciences, Inc.
NPCENeuroPace, Inc.
SRDXSurmodics, Inc.
KIDSOrthoPediatrics Corp.
OSAProSomnus, Inc. Common Stock
AORTArtivion, Inc.
AXGNAxoGen, Inc.
CVRXCVRx, Inc.